Celldex (CLDX) announced positive data from the ongoing Phase 1 study of CDX-622, a novel bispecific antibody that targets two pathways implicated in inflammation and fibrosis. In the study in healthy volunteers, CDX-622 was well tolerated, exhibited a good pharmacokinetic profile, and induced rapid and sustained reductions in serum tryptase, indicative of mast cell inhibition. Based on the data, the company has progressed the study to multiple ascending doses and expects to initiate a Phase 1b proof of mechanism study in patients with mild to moderate asthma next year.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CLDX:
- Celldex initiated with an Outperform at Mizuho
- Celldex initiated with an Underweight at Barclays
- Celldex’s barzo shows strong efficacy in CSU patients, says H.C. Wainwright
- Celldex’s Barzolvolimab Shows Promising Efficacy in Treating Chronic Spontaneous Urticaria Across Patient Subgroups
- Celldex announces new barzolvolimab data at EADV congress